Aptar Pharma, a leading provider of innovative drug delivery systems, in combination with Schott Glass and EMA Pharmaceuticals, announced the launch of Aptar Pharma QuickStart™ for injectable drug development.
‘Aptar Pharma QuickStart’ is a sterile, Ready-To-Use (RTU) drug development support kit designed specifically for research & development labs. A package complete with glass vials, elastomeric stoppers and caps, ‘QuickStart’ provides everything needed for the small volume filling of high value formulations. Also included in the kit are all the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components. Co-developed alongside Schott and EMA Pharmaceuticals, ‘Aptar Pharma QuickStart’ is available to cater to different sizes and configurations of vials, stoppers and caps.
Aptar Pharma’s expertise in device development and formulation helps ensure that QuickStart’s components satisfy all regulatory requirements, allowing users to access commercial scale quality at a development stage cost.
Headquartered in Crystal Lake, Illinois (USA), Aptar Pharma is a leading provider of innovative drug delivery systems to pharmaceutical, consumer healthcare and biotech customers worldwide. The company has broad therapeutic expertise in nasal, pulmonary, injectables, eye care and dermal delivery routes, among others. Aptar has manufacturing facilities in North America, Europe, Asia and South America.